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HPLC method development for fampridine using Analytical 
Quality by Design approach
Offering a systematic and multivariate analysis of 
the analytical procedure, development and vali-
dation of HPLC methods using Quality by Design 
approach are in the limelight of current research 
trends. A new, experimental design-aided HPLC 
method for fampridine was developed and pre-
liminarily validated according to current in-force 
international guidelines for linearity, accuracy, 
robustness and precision.
The method offers a high throughput sample 
analysis, with an elution time of 2.9 minutes, and 
signal detection without excipient interference 
performed at 262 nm. The method proved to be 
linear between 1–15 µg mL–1 (R2 = 0.9996). The 
mean recovery was found to be 98.7 ± 1.9 % in the 
tested range of 2.5–7.5 µg mL–1. Low RSD values 
(< 1 %) were obtained for both model, intra- and 
inter-day precision. The limit of detection and 
limit of quantification were 0.24 and 0.78 µg mL–1, 
resp. The method proved to be applicable for ac-
tive substance assay in a pharmaceutical dosage 
form.
Keywords: Analytical Quality by Design, fampri-
dine, HPLC
 
Multiple sclerosis (MS) is a chronic neuroinflammatory disease that affects approxi-
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probably involved in the onset of the disease, however, the exact cause of MS is still un-
known (1). Fampridine (4-aminopyridine, dalfampridine, Fig. 1) is a recently developed 
therapeutic agent, that complements the currently available disease-modifying treatments 
by ameliorating the walking impairment, a symptom with high prevalence among MS 
patients (2). Fampridine is a broad-spectrum voltage-dependent potassium channel blocker 
first used in electrophysiological studies to determine the role of potassium channels in 
the generation and propagation of neuronal action potentials (3, 4). Following two successful 
phase-3 clinical trials (5, 6), the US Food and Drug Administration (FDA, 2010) and the 
European Medicines Agency (EMA, 2011) approved fampridine for the management of 
walking disability in patients with MS (7, 8).
Fig. 1. Chemical structure of fampridine (4-aminopyridine).
A limited number of analytical methods have been developed for the assay of fampri-
dine. Determination of the active substance and related impurities in the bulk drug or 
formulations has been achieved using UV spectrophotometry (9) or high-performance 
liquid chromatography (HPLC) (10–13). Furthermore, liquid chromatography/mass spec-
trometry (LC-MS) procedures have been developed and applied for the assay of fampri-
dine in biological samples, either individually (14) or simultaneously with other active 
substances (15, 16).
The United States Pharmacopeia’s (USP) monograph for dalfampridine (US name for 
fampridine) describes an HPLC assay procedure that uses as mobile phase methanol and a 
buffer solution containing octanesulfonic acid sodium salt, ammonium acetate and trimethyl-
amine (17). Thomas et al. (10) used a mobile phase (pH = 4.00 ± 0.05) of similar composition for 
the determination of fampridine and potential impurities in the bulk drug. The method descri-
bed by Babu et al. (11) employs as mobile phase A buffer solution of potassium dihydro gen 
phosphate and octanesulfonic acid and as mobile phase B mixture of acetonitrile and mobile 
phase A. Dharani et al. (12) have reported a simpler mobile phase composition, consisting of 
potassium dihydrogen phosphate solution and acetonitrile with an isocratic elution.
A design of experiments (DoE) approach supports the simultaneous variation of mul-
tiple factors at different levels, allowing the detection of both main effects and secondary 
interactions between the studied factors (18, 19). Therefore, DoE provides relevant informa-
tion with a minimal number of performed experiments (20). Based on the results of these 
experiments the optimal run conditions can be statistically determined and the outcome 
of unperformed experiments predicted with high accuracy (21). Pharmaceutical applica-
tions of DoE include the development and optimization of single-component (22, 23) 
and multi-component formulations (24, 25), as well as the development and validation of 
 analytical methods (26, 27).
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The main objective of the present study was to develop and validate a high through-
put HPLC method for the assay of fampridine applying DoE using readily available 
 reagents, thus providing a simple and cost-effective alternative to available techniques. 




HPLC determination was carried out using a LiChrosphere® 60 RP-select B 5 µm, 250 
mm × 4 mm column (Merck KGaA, Germany). The components of the Merck Hitachi HPLC 
system were the following: interface D-7000, quaternary pump L-7100, solvent degasser 
L-7612, autosampler L-7200, column oven L-7360 and DAD detector L-7455. Specific chromato-
grams were analysed using the HSM 4.0 software by Merck Hitachi (Merck Hitachi, Japan).
Reagents
Disodium hydrogen phosphate, monobasic potassium phosphate, orthophosphoric 
acid, sodium hydroxide and HPLC grade methanol (MeOH) were used from Merck 
 (Merck). Gradient grade acetonitrile (ACN) was from VWR International (VWR Inter-
national, France). Dalfampridine USP reference standard was obtained from USP (USP, 
Rockville, MD, USA).
The active substance fampridine (FAM) was obtained from Procos (Procos SpA, Italy). 
Water, purified, was obtained with a Merck Millipore Direct Q, Progard 2® system (Merck 
Millipore, USA).
Selectivity studies were performed based on the qualitative and quantitative compo-
sition of the original product, Fampyra 10 mg prolonged-release tablets, using Hypro-
mellose (Dow Chemical, USA), cellulose, microcrystalline (JRS Pharma, Germany), silica, 
colloidal anhydrous (Evonik Industries, Germany) and magnesium stearate (Faci SpA, 
 Italy) as excipients. The original product was purchased from a local pharmacy.
Preparation of phosphate buffer solution. – Phosphate buffer solution with pH = 6.8 was 
prepared according to the current USP (17).
Preparation of placebo solution (real blank). – The quantities of selected excipients corre-
sponding to one single dose of pharmaceutical formulation were stirred using 900 mL 
phosphate buffer, pH = 6.8. Ten mL of the solution was filtered through a 0.45-µm Chro-
mafil® Xtra PA-45/25 filters (Macherey-Nagel, Germany) and completed to 1 L in a volumetric 
flask with water, obtaining a 1:100 diluted placebo.
Preparation of standard solutions. – The solution of a final concentration of 5 µg mL–1 was 
prepared by dissolving 5 mg FAM in 1 L of 1:100 diluted placebo formulation and com-
pleted to the mark with the same solvent.
The starting solution for linearity testing was prepared by dissolving 20 mg FAM in 
1 L of 1:100 diluted placebo formulation and completed to the mark with the same solvent, 
thus obtaining a final concentration of 20 µg mL–1.
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Chromatographic conditions
Chromatograms were recorded under the conditions obtained by in silico method 
deve lopment optimization, using an isocratic mobile phase consisting of MeOH:ACN:PB 
65:5:30 (%, V/V) (PB – phosphate buffer 1 mmol L–1, pH = 3.0 ± 0.01 adjusted with H3PO4). 
The flow rate was set at 1.0 mL min–1, using a column temperature of 39.5 °C and an injec-
tion volume of 30 µL using the cut method. Analytical signal detection and best chromato-
gram extraction were recorded at 262 nm.
Method optimization
Screening experimental design. – The analytical method was optimized by experimental 
design using the MODDE 12.1 software (Sartorius Stedim Biotech GmbH, Göttingen, Ger-
many). For the best evaluation of the chromatographic method and to profoundly investi-
gate the effects of defined factors on selected responses a full factorial design with three 
center points was chosen. The included factors: flow rate, column temperature and the 
proportion of the phosphate buffer, pH = 3.0, were investigated at three levels, returning 
in 30 experiments (33 = 27 in this case, yielding a total of 30 runs including the three center, 
replicate runs). The level of ACN was kept at a constant ratio of 5 % throughout the method 
development and MeOH proportion was modified according to DoE settings for the 
 percentage of phosphate buffer, pH = 3.0. Samples were analysed in three replicate runs, 
retention time, theoretical plate number and tailing factor were recorded as responses 
(Table I).
Model fitting and analysis of the experimental design. – The experimental model was fitted 
using the partial least squares (PLS) method and the significance was tested by ANOVA 
F-test and its test for lack-of-fit. Further analysis included the evaluation of model perfor-
mance indicators characterizing the factor-response interactions. Generally, a model is 
Table I. Factors and responses defined in the present screening experimental design
Selected factors for the experimental design
Level applied –1 0 1
Flow rate (mL min–1) 0.50 1.00 1.25
Column temperature (°C) 20 30 40
PB proportion in mobile phase (%)a 30 50 70
Responses followed for experimental design assessment
Requirement Min Target Max
Retention time (min) 2 3 5
Theoretical plate number (N)b 2000 – –
Tailing factor 0.8 1.2 2.0
a PB – phosphate buffer, pH = 3.0. 
b Defined per column length.
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considered adequate if the goodness of fit (R2) and goodness of predictability (Q2) tend to 
1.0, but are greater than 0.5 and the difference between the two indicators does not exceed 
0.2–0.3. Model validity, describing the suitability of the selected method for the analysis of 
the design should return values greater than 0.25. Finally, model reproducibility offers 
information about the controllability of the proposed method and is considered acceptable 
if the values are situated above 0.5. In the case of reproducibility, excessively high nume-
rical values (> 0.99) indicate an infinitesimal pure error inside the model and is generally 
observed in highly controlled methods, e.g., HPLC determinations. As model validity is 
closely related to the pure error, low values (< 0.25) might be observed when high repro-
ducibility is attained, and thus the design is considered as acceptable in these particular 
cases as well (19, 28). Furthermore, factor-response interactions were also evaluated by the 
coefficient plot analysis, where model refinement was attained by removing non-signifi-
cant model terms (p > 0.05).
Optimization. – After model fitting and refinement, an optimizer run was carried out 
based on the parameter settings provided by the software. The optimizer run was injected 
five times and the obtained results were compared with the predicted results by the com-
putational program using the prediction spreadsheet option.
Preliminary validation of the method after in silico optimization
Linearity. – Method linearity was tested in the range of 1–15 µg mL–1 through six sam-
ple points 1.0, 2.5, 5.0, 7.5, 10.0, 15.0 µg mL–1. Table samples were prepared by dilution from 
a stock solution of 20 µg mL–1. The determination was repeated five times for each concen-
tration level.
Model selectivity. – Selectivity studies were conducted by recording the chromato-
grams of individual excipient samples, placebo formulation and placebo spiked with FAM 
prepared under the same conditions.
Model accuracy. – Method recovery was evaluated at three points (50, 100 and 150 %) of 
the target concentration. Individual samples were prepared with FAM-spiked placebo and 
repeated three times for each determination.
Robustness. – Method robustness was tested by applying a separate experimental 
 design (Plackett-Burman model, fitted with the multiple linear regression method) (19). 
The model offers the possibility to assess the linear factor-response relationship, but no 
factor interactions can be evaluated by using the disclosed experimental model. In the case 
of robustness testing using experimental designs, four general outcomes (limiting cases) 
of the obtained results are defined. Amongst the various outcomes of the fitted and refined 
Plackett-Burman model, the limiting case of inside specification limits, but non-significant 
relationship is considered as an optimal result for robustness testing. For the robustness 
testing the same factors were defined as described in the previous experimental design 
with the following settings: flow rate 0.95–1.05 mL min–1, column temperature 37.5–41.5 °C 
and the proportion of the phosphate buffer, pH = 3.0, between 28 and 32 (%, V/V). The 
 experimental design returned 11 experimental runs.
Furthermore, method robustness was tested for individual changes in detection 
wavelength at 260 and 264 nm.
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Model precision. – Placebo samples spiked with 5 mg of FAM were prepared on the 
same day by the same analyst and on two different days by two analysts. The analysis was 
carried out on six replicate samples for each determination. Instrument precision was 
tested on five replicate injections of the same sample.
Limit of detection (LOD) and limit of quantification (LOQ). – LOD and LOQ values were 
assessed at a 3:1 and 10:1 signal-to-noise ratio for six and three replicate determinations, resp.
Assay from the pharmaceutical dosage form
Ten tablets of Fampyra 10 mg prolonged-release tablets were pulverized and 200 mg 
of sample, corresponding to 5 mg FAM was admixtured with 500 mL phosphate buffer, pH 
= 6.8, sonicated in an ultrasound bath for 15 min and completed with the same solvent to 
1 L in a volumetric flask. The final sample was filtered through a 0.45-µm Chromafil® Xtra 
PA-45/25 filter discarding the first 5 mL of filtrate. Active substance content was analysed 
from three individual samples.
Statistical analysis
Statistical analyses were carried out using the Minitab 17 software (Minitab Inc., State 
College, PA, USA) and Statistica 8.0 software (StatSoft, Tulsa, OK, USA).
Possible aberrant values in experimental design were detected and excluded using the 
Grubb’s test for outliers at α = 0.05 significance level (p < 0.05).
Shapiro-Wilk’s test was used for the assessment of the normal distribution of the resi-
duals, at a 95 % confidence interval. The null hypothesis, that the residuals do not follow 
a normal distribution, is rejected if W for FAM is greater than the critical tabulated value 
for the number of observations at α = 0.05 and simultaneously p > 0.05. Furthermore, the 
plot of response values vs. corresponding concentrations was calculated with an accep-
tance limit of 2.5 % in comparison to target level response factor in the range of 50–150 % 
and 5.0 % in the range of tested linearity. ANOVA F-test and its test for lack-of-fit were used 
for the significance testing of the calibration curve (CI = 95 %). In order to assess the capa-
bility of the process to comply within specification limits, process capability (Cpk) was 
calculated for the plot of response values vs. corresponding concentrations at ± 10 % speci-
fication limits (acceptance criteria: Cpk > 1.33).
In order to statistically assess the variability of the sets of the results obtained for 
 intra- and inter-day model precision, Student’s t-test was used by setting the significance 
level at α = 0.05.
RESULTS AND DISCUSSION
Screening experimental design
Experiments no. 14 and 15 were excluded from DoE analysis due to inappropriate 
chromatographic results. Grubb’s test performed after the exclusion of the aforementioned 
experiments did not result in the detection of outlier values. The experimental results are 
presented in Table II.
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Significant regression models (p < 0.05) were obtained in the case of all three studied  responses 
(retention time, theoretical plate number and tailing factor); lack-of-fit was only observed in the 
case of retention time (p = 0.003). In the latter case, low model validity is explained by the high 
reproducibility (0.99995) of the replicate runs. The identical results obtained for retention time 
under the replicate runs, as desired in HPLC method development, leads to a low pure error inside 
the model, or namely high reproducibility. Usually, in this case the model error is substantially 
greater than the pure error, resulting in a higher lack-of-fit, which in turn persuades in low model 
validity. The analysis of the model returned good model performance indicator values (Fig. 3a), as 
R2 and Q2 values are situated between 0.63–0.98 and 0.61–0.97, resp. The difference between the 
values of goodness of fit (R2) and goodness of predictability (Q2) does not exceed the requirement 
of 0.2–0.3. The model validity for tailing factor and theoretical plate number is above the minimum 
threshold of 0.25, with values of 0.75 and 0.61, resp. The reproducibility values of the responses are 
all superior to the minimal criteria of 0.5, ranging from 0.80 to 0.99.
The analysis of the coefficient plots (Fig. 3b) revealed that retention time is strongly 
influenced by the flow rate and phosphate buffer proportion and shows a negative correla-
tion with the flow rate and the proportion of the buffer in the mobile phase. Similarly, in 
the case of the tailing factor, the flow rate has a negative impact on response results, whilst 
in terms of buffer concentration a positive correlation was found. The theoretical plate 
number is influenced in an identical manner by the flow rate as observed in the previous 
cases. Contrarily to these, in the case of theoretical plate number a strong influence by 
column temperature can be observed, whilst the effect of the phosphate buffer portion is 
negligible. Although indicating a curved surface inside the model, the detected factor 
 interactions (flow × PB) and quadratic terms (flow × flow, PB × PB) for retention time and 
theoretical plate number were retained, as deletion of these particular influencing factors 
would result in performance model indicator deterioration.
Optimizer run. – Based on the fitted and refined experimental design, a placebo sample 
spiked with 5 mg FAM was injected five times using the factor settings offered by the soft-
ware and the results were compared with those predicted by the computational design. 
The optimized factor settings and comparison of the predicted vs. observed result sets are 
presented in Table III.
Under the set of experimental conditions (flow rate 1.0 mL min–1, column temperature 
39.5 °C and 30 % PB) the prediction of the program proved to be reliable, as a sample reten-
tion time of 2.88 min is marginally inferior to the foreseen 2.91 min and a peak tailing of 
1.69 is properly close to the predicted 1.70. Regarding the values of the theoretical plate 
number, a higher value was observed in comparison to the predicted one, but still lying 
within the confidence interval provided by the software. A typical chromatogram under 
the optimized chromatographic conditions is presented in Fig. 2b.
Model validation results
Selectivity. – Under proposed settings, FAM can be identified as a sharp, well-defined 
peak 262 nm, from both the standard solution and pharmaceutical dosage form, in com-
parison to placebo formulation (see Figs. 2a-c); no interference of the excipients can be 
observed (see Fig. 2a).
Linearity. – The method proved to be linear in the tested range of 1–15 µg mL–1, with a 
coefficient of determination of R2 = 0.9996. The Shapiro-Wilk’s test for the normal distribu-
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tion of the residuals was passed, as the obtained WFAM  = 0.866 was greater than the critical 
threshold of WCRIT. = 0.788 (n = 6, α = 95 %), p = 0.212. The ANOVA F-test revealed a signifi-
cant relationship between the predictors and responses (p < 0.05) and no lack-of-fit was 
observed (p > 0.05). The capability analysis of the plot of response values vs. concentration 
resulted in a Cpk = 1.72, indicating that the model is well controlled within the proposed 
linearity range. Statistical results are given in Table IV.
Robustness. – The method proved to be robust in the tested range as minor changes in 
the chromatographic conditions did not influence the detectability of the analyte (Table V). 
This is also supported by the results of the Plackett-Burman experimental design, where 
no significant relationship was found between the factors and responses in the case of 
tailing factor and theoretical plate number (R2 < 0.5). Concurrently, the low goodness of 
predictability values indicates that the model could not detect remarkable modifications 
in response values that are due to minor changes in factor settings.
Fig. 2. a) Chromatogram of placebo sample, b) typical chromatogram of placebo spiked with fampri-
dine (5 µg mL–1), c) chromatogram of a real sample obtained from the original commercial product 
(5 µg mL–1 FAM).
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In contrast to the screening experimental design, in the case of the Plackett-Burman 
model higher model validity values are attained (Fig. 3c), whereas in the case of retention 
time a negative to positive switch is observed, indicating that the model is valid in the 
proposed testing range.
The analysis of the coefficient plots (Fig. 3d) shows that the theoretical plate number 
and tailing factor are not influenced in a significant manner by any of the defined factors. 
In contrast, retention time is strongly influenced by the flow rate and the proportion of the 
phosphate buffer in the mobile phase, both having a negative correlation with the men-
tioned response. These tendencies are similar to those observed in the screening experi-
mental model. The existence of strong factor to response correlations explains the higher 
R2 and Q2 values, since, as expected, minor changes in flow rate and mobile phase compo-
sition have a slight effect on the retention of the active substance to the column’s stationary 
phase, thus modifying retention time in a systematic manner.
Negligible changes in detection wavelength (± 2 nm) did not influence the selected 
responses in a critical manner, resulting in a tailing factor of 1.66 and a theoretical plate 
number of 4712 in both cases, and a recovery of 99.5 and 99.9 % at 260 and 264 nm, resp.
Table IV. Model analytical merits of the developed HPLC method
Parameter Result Statistical result
Linearity (µg mL–1) 1–15 µg mL–1
R2 = 0.9996
WFAM = 0.866a (p = 0.212)
F = 22,132.69 (p < 0.05)b
F = 2.35 (p > 0.05)c
Cpk = 1.72d
Accuracy (%) 98.7 ± 1.9 R2 = 0.9998
Intraday precision 
(RSD, %)e,f 0.4–0.7




t<analyst 1 day 1 vs. analyst 1 day 2> = 1.682 
p = 0.123 
t<analyst 2 day 1 vs. analyst  day 2> = 0.237 
p = 0.816
Instrument precision 
(RSD, %)g 0.5 –
LOD (µg mL–1) 0.24 –
LOQ (µg mL–1) 0.78 –
Assay from tablets (%)h,i 100.3 –
a WCRIT. = 0.788 – critical tabulated value of Shapiro-Wilk’s test.
b Critical tabulated value of ANOVA F-test, F = 4.20.
c Critical tabulated value of ANOVA F-test for lack-of-fit, F = 2.70.
d Requirement, Cpk > 1.33.
e Critical value of t = 2.228, df = 10.
f n = 6, g n = 5, h n = 3.
i Compliance with the label claim.
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Accuracy. – The mean recovery of the method was 98.7 %, value lying in-between 95.8 
and 101.8 % for the 50–150 % interval (Tables IV and VI). Also, the linearity of the spiked 
samples shows a good linear correlation, with R2 = 0.9998.
Precision. – The performed Student’s t-test revealed that there is no statistical difference 
between the sample set prepared by the same analyst on the same day (intra-day precision) 
and between the two analyst’s sample set prepared on two different days (inter-day preci-
sion). The obtained results showed low variability between the samples, with an RSD of 
0.6 % (100.5–103.3 %). An instrument precision with an RSD of 0.5 % (99.9–101.3 %) was 
 obtained after five successive injections of the same sample solution (Tables IV and VI).
Limit of detection (LOD) and limit of quantification (LOQ). – The limits of detection and 
quantification of the developed method are 0.24 and 0.78 µg mL–1, resp.
Assay of the pharmaceutical dosage form
Three replicate samples yielded an average recovery of 100.6 % (RSD = 0.7 %) from 
FAM tablet formulation (Tables IV and VI) (Fig. 2c).
Method benefits
The proposed analytical method offers a high throughput analysis for FAM and was 
aimed to be useful in the assay of the active pharmaceutical ingredient from tablets and 


















1 1.05 28 37.5 2.85 1.81 4847.0
2 1.05 32 37.5 2.85 1.81 4847.0
3 1.05 32 41.5 2.72 1.90 5003.0
4 0.95 32 41.5 3.01 1.79 5247.0
5 1.05 28 41.5 2.92 1.80 5078.0
6 0.95 32 37.5 2.97 1.81 4857.0
7 0.95 28 41.5 3.18 1.90 5032.5
8 0.95 28 37.5 3.14 1.84 4792.5
9 1.00 30 39.5 2.87 1.71 4991.0
10 1.00 30 39.5 2.88 1.59 4772.0
11 1.000 30 39.5 2.91 1.82 4576.0
Average 2.93 1.79 4913.0
Difference to predicted optimizer results +0.02 +0.09 +468.0
Difference to observed optimizer results +0.06 +0.10 +141.4
a Defined per column length.
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dissolution profile samples. When compared to the already available methods (see Table 
VII) that aimed only the assay of the active substance (12), the novel method has a lower 
linearity range of 1–15 µg mL-1 vs. 20–80 µg mL–1. Comparing the other analytical valida-
tion parameters, the novel method surpasses the currently accessible method (12), espe-
Table VI. Results obtained for model studies of accuracy, precision and pharmaceutical dosage form
Model accuracy study
FAM in the real blank
Theoretical 









2.500 2.503 100.1 ± 1.3 1.3
5.000 4.948 99.0 ± 2.2 2.2
7.500 7.273 97.1 ± 0.8 0.9




in sample  
(µg mL–1)
Sample no.
Inter-day precision Intra-day precision
Average (%)Concentration found (%)
Analyst 1 Analyst 2 Analyst 2
5.000
1 101.8 102.6 102.5
102.1
2 102.0 101.8 103.0
3 100.5 101.3 102.1
4 102.1 102.8 101.9
5 102.4 103.3 101.9
6 101.5 102.2 102.0
Average 101.7 102.3 102.2
RSD (%) 0.6 0.7 0.4 0.6
Assay of pharmaceutical dosage form
Expected FAM 







a n = 9, b n = 27, c Based upon label claim.
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cially in terms of LOD and LOQ of 0.24 µg mL–1 vs. 0.71 µg mL–1 and 0.78 µg mL–1 vs. 2.16 
µg mL–1, resp. Furthermore, in terms of retention time, the proposed method performs 
better or equivalently in contrast to other analytical reports. Taking into consideration the 
FDA requirement (29) for the volume of dissolution media (900 mL) and the amount of the 
active substance (10 mg), a general concentration span between 1.11 µg mL–1 (10 % of active 
substance dissolved) and 11.11 µg mL–1 (100 % of active substance dissolved) would be 
obtained at specified sampling times (0.5–12 h). As method validation was carried out 
nearby the aforementioned concentration range, the novel method might perform wor-
thier when compared with other methods and is applicable without time-consuming 
sample preparation. Furthermore, the developed method might be considered as a surro-
gate for the available compendial method, having its benefit in the simpler and more avail-
able mobile phase components.
CONCLUSIONS
The developed method offers high throughput, cost-effective sample analysis from 
both bulk samples and pharmaceutical dosage form. The applied computational method 
development offers the possibility to collect in silico information regarding the chromato-
graphic particularities following modifications in factor settings. The newly proposed 
method for the assay of fampridine was preliminarily validated as per the currently avail-
able international guidelines and fulfilled the model validation requirements for linearity, 
accuracy, robustness and precision. Furthermore, the development and validation of the 
present method employing Quality by Design approach support the essentiality of soft-
ware-controlled methodology in modern pharmaceutical research and development.
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